Symptomatic osteoporosis in two young HIV-positive African women

Stephens, Elizabeth; Das, Rita; Madge, Sara; Barter, Janet; Johnson, Margaret

doi:10.1097/00002030-199912240-00022

Cited by 56 publications

(17 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, it is remarkable that very few non-traumatic fractures have been reported in HIV-infected patients. [10][11][12][13] Whether this represents a real absence of fractures or simply underreporting requires clarification. This report describes the clinical and laboratory characteristics of fragility fractures among HIV-infected patients, as well as their clinical management.…”

Section: Introductionmentioning

confidence: 99%

Fragility Fractures in HIV-Infected Patients: Need for Better Understanding of Diagnosis and Management

McComsey

Huang

Woolley

et al. 2004

Journal of the International Association of Physicians in AIDS

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Fragility Fractures in HIV-Infected Patients: Need for Better Understanding of Diagnosis and Management

McComsey

Huang

Woolley

et al. 2004

Journal of the International Association of Physicians in AIDS

View full text Add to dashboard Cite

show abstract

“…It is stated that BMD is moreover constant or variable [61,62,[64][65][66]. Young patients are at a low risk of incurring bone fracture, but older patients are at a much higher risk due to ageing [67][68][69][70][71].…”

Section: Bone Loss and Antiretroviral Therapymentioning

confidence: 99%

HIV-associated osteoporosis

Qadir

Ali

Muhammad

et al. 2015

Reviews in Medical Microbiology

View full text Add to dashboard Cite

“…The precise mechanism is unknown, as is the association with therapy or any specific antiretroviral drugs. Although to date reports of bone fractures are rare (203), the longterm consequences of osteopenia in HIV-1-seropositive patients are unknown.…”

Section: Bone Disease Backgroundmentioning

confidence: 99%

Rapid Communications: Management of Metabolic Complications Associated With Antiretroviral Therapy for Hiv-1 Infection: Recommendations of an International Aids Society-Usa Panel

&NA;

2002

Infectious Diseases in Clinical Practice

View full text Add to dashboard Cite

Objective: Alterations in glucose and lipid metabolism, lactic acidemia, bone disorders, and abnormal body fat distribution have been recognized recently as frequent complications associated with HIV-1 infection and potent antiretroviral therapy, but limited data are available regarding the appropriate management of these disorders. These recommendations were developed to guide physicians actively involved in HIV care in the management of metabolic complications that occur primarily within the context of potent antiretroviral therapy.Participants: A 12-member panel representing international expertise in HIV-1 patient care, antiretroviral therapy, and endocrine and metabolic disorders was selected in the spring of 2000 by the International AIDS Society-USA, a not-for-profit physician education organization. Panel members met in closed meetings beginning in May 2000. All work was funded by the International AIDS Society-USA; the panel members are not compensated for their participation.Evidence: The panel reviewed published results of clinical, epidemiologic, and basic science studies and data and abstracts presented at research conferences, primarily from 1997 to 2002. The panel also considered studies of the pathophysiology and treatment of similar metabolic abnormalities in noninfected persons. Emphasis was placed on results from prospective, randomized, controlled clinical trials when available.Process: For each metabolic complication, 1 or more member(s) reviewed and presented all available evidence to the panel, and then wrote a summary of the evidence and preliminary recommendations. 257full group consensus. The summaries were combined into a single working document and all panel members edited and approved all subsequent drafts. Conclusions:Carefully controlled studies to determine the incidence, etiology, risk factors, and most appropriate treatments for metabolic complications in HIV-1 infection are urgently needed. In the absence of these data, and to prevent acute illness and mitigate long-term risks, the panel recommends routine assessment and monitoring of glucose and lipid levels and assessment and monitoring of lactic acidemia and bone abnormalities if clinical signs or symptoms are detected. With the exception of body fat distribution abnormalities, specific treatments for these complications are also recommended. Successful long-term antiretroviral therapy will require diligent monitoring and preemptive treatment of metabolic complications to optimize the riskbenefit ratio of antiretroviral therapies.Key Words: HIV-Antiretroviral-Insulin resistance-Hyperlipidemia-Lipodystrophy-Lactic anemia-Osteoporosis-AIDS-Guidelines-Metabolic complications.The availability of potent combination antiretroviral regimens has resulted in a dramatic reduction in HIV-1-associated morbidity and mortality in the developed world (1). However, the optimism generated by such treatment has been tempered by the recognition of an increasing array of adverse metabolic effects, including insulin resistance and glucose intol...

show abstract

Symptomatic osteoporosis in two young HIV-positive African women

Cited by 56 publications

References 2 publications

Fragility Fractures in HIV-Infected Patients: Need for Better Understanding of Diagnosis and Management

Fragility Fractures in HIV-Infected Patients: Need for Better Understanding of Diagnosis and Management

HIV-associated osteoporosis

Rapid Communications: Management of Metabolic Complications Associated With Antiretroviral Therapy for Hiv-1 Infection: Recommendations of an International Aids Society-Usa Panel

Contact Info

Product

Resources

About